Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat Maintenance in Hodgkin's Lymphoma (PATH)
NCT01034163Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of panobinostat in Hodgkin lymphoma (HL), sponsored by Novartis. Started Jun 2010; status: completed.
02
Drugs
panobinostat
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01034163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01034163.